Results 21 to 30 of about 756,852 (217)
Clinical predictors for the prognosis of myasthenia gravis
BMC Neurology, 2017 Background Clinical predictors for myasthenia gravis relapse and ocular myasthenia gravis secondary generalization during the first two years after disease onset remain incompletely identified.
Lili Wang, Yun Zhang, Maolin He
doaj +1 more source
Eculizumab as a promising treatment in thymoma-associated myasthenia gravis
Therapeutic Advances in Neurological Disorders, 2020 Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis.
Valentina Vélez-Santamaría +5 more
doaj +1 more source
Sotalol‐induced generalized and ocular myasthenia gravis [PDF]
Clinical Case Reports, 2019 Abstract We present a patient with end‐stage hypertrophic cardiomyopathy who was suffering from ocular and generalized forms of myasthenia gravis as an uncommon neurological complication of sotalol. This case report warns clinicians to maintain caution over rare side effects of medication, which could be confused with the clinical ...
Mohammadbagher Sharifkazemi, Farzad Ziya
openaire +3 more sources
Nipocalimab Dose Selection in Generalized Myasthenia Gravis. [PDF]
CPT Pharmacometrics Syst PharmacolABSTRACT Nipocalimab is a fully human immunoglobulin G (IgG)1 monoclonal antibody (mAb) designed to selectively block the IgG binding site of neonatal fragment crystallizable receptor (FcRn) to inhibit IgG recycling and decrease circulating IgG, including pathogenic IgG autoantibodies (such as antiacetylcholine receptor, anti‐muscle ...
Valenzuela B +8 more
europepmc +3 more sources
Diplopia in a patient presenting with “blurred vision”: a case report
Journal of Medical Case Reports, 2023 Background Myasthenia gravis is an autoimmune condition affecting the neuromuscular junction and causing muscle weakness along with fatigue (myasthenia).
Anil Harrison +3 more
doaj +1 more source
Chronic mimics of myasthenia gravis: a retrospective case series
, 2023 Myasthenia gravis often presents a diagnostic challenge and may be misdiagnosed, particularly in seronegative disease with active symptoms. We retrospectively evaluated 61 patients following the introduction of single fibre electromyography at our ...
Winkel, Antony +2 more
core +1 more source
Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis : a genome-wide association study [PDF]
, 2022 Myasthenia gravis is a chronic autoimmune disease characterized by autoantibody-mediated interference of signal transmission across the neuromuscular junction.
Tienari, Pentti J. +5 more
core +1 more source
Angewandte Chemie, EarlyView.Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma +5 more
wiley +2 more sources
Sensitivity of MG‐ADL for generalized weakness in myasthenia gravis [PDF]
European Journal of Neurology, 2018 Background and purposeMyasthenia gravis activities of daily living (MG‐ADL) is a commonly used questionnaire in MG trials. To investigate whether MG‐ADL is equally sensitive to oculobulbar and generalized weakness, its correlation with the oculobulbar and generalized domain of the quantitative myasthenia gravis (QMG) score was analyzed (QMGob and ...
Meel, R.H.P. de +4 more
openaire +3 more sources
Asymmetric pattern in generalized myasthenia gravis
Medicine, 2018 Abstract Rationale: Myasthenia gravis (MG) is an uncommon autoimmune disease mediated by antibodies that attack the postsynaptic acetylcholine receptors (AchRs) at the neuromuscular junction, causing fluctuating muscle weakness, aggravated with use, and relieved with rest.
de Carvalho, Thiago Pereira +6 more
openaire +2 more sources